Alkermes Files Routine 8-K, Confirms Nasdaq Listing & Ireland Address

Ticker: ALKS · Form: 8-K · Filed: 2024-01-08T00:00:00.000Z

Sentiment: neutral

Topics: administrative, corporate-governance, regulatory-filing

TL;DR

**Alkermes filed a routine 8-K, no new news for investors.**

AI Summary

Alkermes plc. filed an 8-K on January 8, 2024, to report a current event. This filing is a routine administrative update, primarily confirming the company's registration details, such as its address in Dublin, Ireland, and its trading symbol ALKS on the Nasdaq Global Select Market. For investors, this filing is a standard procedural disclosure and does not contain new financial or operational information that would directly impact the stock's value.

Why It Matters

This filing is a standard administrative update, confirming basic company information. It does not contain new material information that would typically affect an investor's decision.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing and does not introduce any new financial or operational risks to the company.

Analyst Insight

This filing is purely administrative and provides no new material information to act upon. Investors should continue to monitor for more substantive filings like earnings reports or significant corporate actions.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by Alkermes plc.?

This 8-K filing by Alkermes plc. is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting an event that occurred on January 8, 2024. It primarily serves as a routine administrative disclosure, confirming company details.

What is the trading symbol and exchange for Alkermes plc. ordinary shares?

The trading symbol for Alkermes plc. ordinary shares is ALKS, and they are registered on the Nasdaq Global Select Market.

Where are Alkermes plc.'s principal executive offices located?

Alkermes plc.'s principal executive offices are located at Connaught House, 1 Burlington Road, Dublin 4, Ireland, D04 C5Y6.

What is the par value of Alkermes plc.'s ordinary shares?

The par value of Alkermes plc.'s ordinary shares is $0.01.

Does this 8-K filing contain any new financial statements or significant operational updates?

No, this 8-K filing is categorized under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' but the content provided is a standard cover sheet and does not include new financial statements or significant operational updates beyond basic company identification and registration details.

Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-08 07:00:17

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 8, 2024, Alkermes plc made available a copy of the corporate presentation to be displayed during its presentation at the J.P. Morgan Healthcare Conference on January 10, 2024. A copy of the presentation is furnished herewith as Exhibit 99.1 and is incorporated by reference in this Item 7.01. The information in this Item 7.01, and in Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Sta tements and Exhibits

Item 9.01 Financial Sta tements and Exhibits. (d) Exhibits EXHIBIT INDEX Exhibit No. Description 99.1 Alkermes plc corporate presentation . 104 Cover page interactive data file (embedded within the Inline XBRL document). 2 SIGNA TURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALKERMES PLC Date: January 8, 2024 By: /s/ David J. Gaffin David J. Gaffin Secretary 3

View on Read The Filing